Reaction of lung cancer to self-administration of cannabidiol
Here is the report of a published case in the medical journal SAGE, where the doctors claimed that "the CBD could play an important role in a malignant tumor".
Despite the creation of new drugs, lung cancer is associated with a very negative prognosis. Some targeted therapies improve outcomes, but many patients have only partial responses and relapse during follow-up. Therefore, re-evaluation of therapies used to treat other non-cancer diseases may be necessary.
We report here the case of a patient suffering from pulmonary adenocarcinoma who, after declining chemotherapy and radiotherapy, presented a tumor response after self-administration of cannabidiol. Previous work has shown that cannabidiol may have properties antineoplastic and improve the immune response to cancer. The data presented here indicate that cannabidiol may have resulted in a striking tumor response in a patient with lung cancer.
Challenge to improve the outcomes of cancer patients
To improve the prognosis of lung cancer research has led to the development and evaluation of new drugs whose mechanisms of action differ from conventional chemotherapy drugs used for many years in the world. Major efforts are currently underway to develop and evaluate the potential of targeted therapies and immunotherapy in lung cancer that lead to better clinical outcomes. Thus, targeted therapy replaces conventional chemotherapy as a standard treatment for patients with targeted oncogenic leads. However, it must be recognized that the responses to these agents are still partial, the tumors occurring during the follow-up because of the genetic heterogeneity of the tumors and it is very difficult to obtain a complete response in patients with lung cancer .
The challenge of optimizing the outcomes of lung cancer patients leads to the evaluation of alternative medicines that, alone or in combination, can improve the response and survival of lung cancer patients. Therefore, it is interesting to continue the development of new drugs or even established therapies previously used to treat non-malignant diseases (reorientation of drugs) that could have an effect on lung cancer in vitro and / or in vivo.
A possible example: cannabidiol (CBD)
A non-psychoactive compound of cannabis sativa: CBD, which has been used in the management of several non-oncological pathologies, could be a potential drug in the treatment of cancer.
This is the miraculous story of a cancer patient who saw his tumors shrink by taking drops ofcannabidiol oil (CBD) every day.
The man of 81, who has not been identified, has refused chemotherapy several times. Instead, the ex-smoker chose to take CBD oil for two months to attack his cancer.
In September 2017: Just two months before the CT scan showed that his tumor had halved in size, this patient told the doctor he had started taking CBD oil.
At first, he took two drops twice a day for a week, before increasing his dose to nine drops twice a day until the end of September.
Then he stopped taking the oil a week after his positive result in November because he "did not like the taste".
Doctors have recently released amazing scans showing how it helped. The story was published in a medical journal by doctors from Stoke-on-Trent, England.
of the scintigraphy breathtaking, showing how it halved the size of its tumors and reversed the progression of its disease.
However, experts have warned that this is just one of many cases. Claims that cannabis or any of its derived compounds could have a significant impact on cancer are not yet proven.
Scanners showed a shadow in his left lung, which turned out to be a cancerous tumor of 2,5 cm on 2,5 cm. The disease had also spread to his lymph nodes in July 2017.
In November 2017 the same tumors reduced to 1,3 cm on 0,6 cm.
Dr. Sulé-Suso and colleagues also found a "significant reduction" in the size and number of mediastinal lymph nodes.
Scientists believe that CBD produces oxygenated chemicals in the body that can cause cancer cell death.
Ian Hamilton, a York University researcher who did not treat the patient, told mail Online that this case report was "very important".
This unique case study adds to many others that offer promising perspectives in the use of CBD products for the treatment of cancer. I think there is real potential with the CBD, but there is also a lot of false hope. This type of case study is important, but it is unlikely to change medical practice.
A larger randomized controlled trial will be needed to distinguish what is due to the placebo effect.
In this specific case, the patient had previously been diagnosed with chronic obstructive pulmonary disease (COPD), a debilitating lung condition that causes shortness of breath. In addition to having COPD, he smoked about 20 cigarettes a day when he was between 20 and 30. Both are risk factors for lung cancer.
The man was diagnosed with lung adenocarcinoma in October 2016, after going to his GP, complaining that his shortness of breath was worsening.
No other changes in diet, medication or lifestyle were noted, which led physicians to believe that CBD oil was the main driver of tumor reduction.
Lung adenocarcinoma accounts for about 80% of cases in the UK. About 44 500 people are diagnosed with lung cancer each year in the UK. It is the sixth most common cancer in France (11 600 new annual cases in 2012) and the fourth leading cause of cancer deaths in France and Europe. In the United States This figure is about 260 000. Only 15% of patients with lung adenocarcinoma survive for five years, according to statistics.